biotricity Finalizes Partnership Expansion with the University of Calgary

REDWOOD CITY, Calif., Oct. 25, 2016 -- biotricity inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has finalized the expansion of their long-term research partnership with the University of Calgary. The vision of this expanded partnership is to apply biotricity’s technology in a variety of areas that lend themselves to remote monitoring. Working with clinical leaders in a number of divisions via the Cummings School of Medicine Department of Anesthesia, biotricity will develop prototype remote monitoring mobile devices in a number of clinical settings, including peri-operative medicine, maternal/fetal medicine and acute and chronic care medicine in order to facilitate the application of “smart” medical grade wearables to the hospital and out-patient settings, and drive the innovation and development into new and never before thought of areas.

“We are thrilled to expand on our already successful relationship with the University of Calgary,” said Waqaas Al-Siddiq, Founder and CEO of biotricity. “Their participation is an important step in helping us realize our goal, which is to take what we learn from this research and align it with our investigation into predictability and artificial intelligence for the next generation of healthcare.”

Dr. David Liepert, a clinical associate professor in the Department of Anesthesia and Peri-Operative Medicine explained: “Just as logistics and ‘on-time’ supply chain management revolutionized industry in the 90’s, clinicians are realizing that individualized ‘on-time/real-world’ care will revolutionize medicine, allowing us to reduce costs and improve outcomes simultaneously. This is particularly obvious in the growing field of peri-operative medicine, where interactive pre-operative optimization and on-going post-operative hospital and outpatient recovery monitoring, including activity, compliance and physiology combined with early client-specific intervention are already demonstrating those benefits. We look forward to biotricity’s leadership and support as we coordinate clinical medicine and biomedical engineering to develop more efficient, effective and timely solutions for client-specific care.”

Additionally, and in related news, biotricity founder and CEO Waqaas Al-Siddiq was also named an advisor to members of the University of Calgary’s School of Medical and Biomedical Engineering.

Dr. Liepert added, “We look forward to capitalizing on Mr. Al-Siddiq's recognized expertise in wearable biometric monitoring, connectivity and data processing for both our University of Calgary’s Medical and Biomedical Engineering students through his advisory role under this expanded partnership.”

biotricity’s goal is to develop a series of clinically accurate devices that are applicable in both clinical and home-based settings. The focus of this expanded partnership will be to investigate and to develop solutions for the fetal monitoring and sleep apnea markets among others, while also executing our business plan to roll out bioflux for MCT and biolife as a premier life-enhancing consumer wearable,” added Al-Siddiq.

About biotricity, Inc.

biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com. 

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
[email protected], 508-429-5988
Richard Smith,
[email protected], 978-433-3304

Investor Relations:
Michael Koehler
Liolios Group, Inc.
[email protected]
949-574-3860